A carregar...
Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D
As part of an ongoing effort at Amgen to develop a disease-modifying therapy for Alzheimer's disease, we have previously used the aminooxazoline xanthene (AOX) scaffold to generate potent and orally efficacious BACE1 inhibitors. While AOX-BACE1 inhibitors demonstrated acceptable cardiovascular...
Na minha lista:
Publicado no: | Medchemcomm |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Royal Society of Chemistry
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6072065/ https://ncbi.nlm.nih.gov/pubmed/30108829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c7md00106a |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|